{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:46:15Z","timestamp":1775634375531,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":959,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NIH Center for HIV\/AIDS Vaccine Immunology (CHAVI)","award":["UO1-AI067854"],"award-info":[{"award-number":["UO1-AI067854"]}]},{"name":"Bill & Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD)\/Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC)","award":["38619"],"award-info":[{"award-number":["38619"]}]},{"name":"Department of Veterans Affairs Medical Center, Research Services"},{"name":"NIH training grant","award":["AI007439"],"award-info":[{"award-number":["AI007439"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.virol.2010.08.028","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T01:03:14Z","timestamp":1285203794000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC"],"prefix":"10.1016","volume":"408","author":[{"given":"Tara G.","family":"Edmonds","sequence":"first","affiliation":[]},{"given":"Haitao","family":"Ding","sequence":"additional","affiliation":[]},{"given":"Xing","family":"Yuan","sequence":"additional","affiliation":[]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[]},{"given":"Kendra S.","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Joan A.","family":"Conway","sequence":"additional","affiliation":[]},{"given":"Lindsay","family":"Wieczorek","sequence":"additional","affiliation":[]},{"given":"Bruce","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Polonis","sequence":"additional","affiliation":[]},{"given":"John T.","family":"West","sequence":"additional","affiliation":[]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[]},{"given":"John C.","family":"Kappes","sequence":"additional","affiliation":[]},{"given":"Christina","family":"Ochsenbauer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0005","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1371\/journal.pmed.0020025","article-title":"The Global HIV\/AIDS Vaccine Enterprise: scientific strategic plan","volume":"2","year":"2005","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"Baba","year":"2000","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0015","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1128\/jvi.71.5.3444-3450.1997","article-title":"Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions","volume":"71","author":"Bastiani","year":"1997","journal-title":"J. Virol."},{"issue":"Pt 3","key":"10.1016\/j.virol.2010.08.028_bb0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1099\/vir.0.81200-0","article-title":"Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein","volume":"87","author":"Bentham","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"23","key":"10.1016\/j.virol.2010.08.028_bb0025","doi-asserted-by":"crossref","first-page":"13232","DOI":"10.1128\/JVI.78.23.13232-13252.2004","article-title":"Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies","volume":"78","author":"Binley","year":"2004","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.virol.2010.08.028_bb0030","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1128\/JVI.01762-08","article-title":"Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C","volume":"82","author":"Binley","year":"2008","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.virol.2010.08.028_bb0035","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/JVI.02011-06","article-title":"Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites","volume":"81","author":"Brown","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/jvi.68.2.654-660.1994","article-title":"Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses","volume":"68","author":"Chen","year":"1994","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"issue":"6251","key":"10.1016\/j.virol.2010.08.028_bb0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/342816a0","article-title":"Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro","volume":"342","author":"Daly","year":"1989","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.0.CO;2-F","article-title":"A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates","volume":"40","author":"Darden","year":"2000","journal-title":"Cytometry"},{"issue":"Pt 5","key":"10.1016\/j.virol.2010.08.028_bb0060","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1099\/0022-1317-82-5-1027","article-title":"The \u201ccleavage\u201d activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring \u201c2A-like\u201d sequences","volume":"82","author":"Donnelly","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"Pt 5","key":"10.1016\/j.virol.2010.08.028_bb0065","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1099\/0022-1317-82-5-1013","article-title":"Analysis of the aphthovirus 2A\/2B polyprotein \u201ccleavage\u201d mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal \u201cskip\u201d","volume":"82","author":"Donnelly","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/516443","article-title":"Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group","volume":"175","author":"D'Souza","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0075","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report","volume":"4","author":"Fenyo","year":"2009","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0080","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1128\/jvi.71.5.3588-3596.1997","article-title":"Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity","volume":"71","author":"Fortin","year":"1997","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2010.08.028_bb0085","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/jvi.69.3.1984-1989.1995","article-title":"Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix","volume":"69","author":"Freed","year":"1995","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.virol.2010.08.028_bb0090","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1128\/JVI.00138-10","article-title":"Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime\/boost vaccination","volume":"84","author":"Freel","year":"2010","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jmv.20770","article-title":"A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1","volume":"79","author":"Garcia-Perez","year":"2007","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.virol.2010.08.028_bb0100","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1128\/jvi.70.4.2586-2592.1996","article-title":"Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules","volume":"70","author":"Gauduin","year":"1996","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2010.08.028_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/14760584.5.3.347","article-title":"Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates","volume":"5","author":"Haynes","year":"2006","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1016\/j.virol.2010.08.028_bb0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.virol.2005.05.002","article-title":"The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles","volume":"338","author":"Herrera","year":"2005","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0115","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/JVI.75.2.1077-1082.2001","article-title":"LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission","volume":"75","author":"Hioe","year":"2001","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.virol.2010.08.028_bb0120","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1056\/NEJMra066267","article-title":"An HIV vaccine-evolving concepts","volume":"356","author":"Johnston","year":"2007","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.virol.2010.08.028_bb0125","doi-asserted-by":"crossref","unstructured":"Jones, J., Whitford, W., Wagner, F., and Kutsch, O. (2007). Optimization of HIV-1 infectivity assays. Biotechniques 43(5), 589-90, 592, 594.","DOI":"10.2144\/000112624"},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/jvi.65.2.583-588.1991","article-title":"Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells","volume":"65","author":"Kaminchik","year":"1991","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.virol.2010.08.028_bb0135","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.virol.2010.08.028_bb0140","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.1128\/JVI.76.17.8776-8786.2002","article-title":"Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency","volume":"76","author":"Kutsch","year":"2002","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.virol.2010.08.028_bb0145","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1073\/pnas.0306764101","article-title":"Dynamics of HIV-1 recombination in its natural target cells","volume":"101","author":"Levy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.virol.2010.08.028_bb0150","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.virol.2010.08.028_bb0155","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.01730-06","article-title":"Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2010.08.028_bb0160","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1128\/JVI.74.8.3859-3870.2000","article-title":"A block to human immunodeficiency virus type 1 assembly in murine cells","volume":"74","author":"Mariani","year":"2000","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.virol.2010.08.028_bb0170","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1128\/JVI.76.10.4810-4821.2002","article-title":"Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells","volume":"76","author":"Mascola","year":"2002","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.virol.2010.08.028_bb0175","doi-asserted-by":"crossref","first-page":"10103","DOI":"10.1128\/JVI.79.16.10103-10107.2005","article-title":"Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines","volume":"79","author":"Mascola","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0180","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/JVI.79.2.771-779.2005","article-title":"Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins","volume":"79","author":"Mascola","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.08.028_bb0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.immunol.24.021605.090605","article-title":"HIV vaccines","volume":"24","author":"McMichael","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.virol.2010.08.028_bb0190","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays","volume":"Chapter 12","author":"Montefiori","year":"2005","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.virol.2010.08.028_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.virol.2010.08.028_bb0200","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1371\/journal.pmed.0040348","article-title":"Antibody-based HIV-1 vaccines: recent developments and future directions","volume":"4","author":"Montefiori","year":"2007","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.virol.2010.08.028_bb0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1084\/jem.20091281","article-title":"Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines","volume":"207","author":"Moody","year":"2010","journal-title":"J. Exp. Med."},{"issue":"25","key":"10.1016\/j.virol.2010.08.028_bb0210","doi-asserted-by":"crossref","first-page":"15131","DOI":"10.1073\/pnas.2436476100","article-title":"Transfer of neutralizing IgG to macaques 6h but not 24h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development","volume":"100","author":"Nishimura","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0215","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COH.0b013e32832f011e","article-title":"New virologic reagents for neutralizing antibody assays","volume":"4","author":"Ochsenbauer","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"15","key":"10.1016\/j.virol.2010.08.028_bb0220","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1128\/JVI.76.15.7518-7527.2002","article-title":"Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex","volume":"76","author":"Ochsenbauer-Jambor","year":"2002","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2010.08.028_bb0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2144\/000112072","article-title":"T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication","volume":"40","author":"Ochsenbauer-Jambor","year":"2006","journal-title":"Biotechniques"},{"key":"10.1016\/j.virol.2010.08.028_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.24.021605.090557","article-title":"GP120: target for neutralizing HIV-1 antibodies","volume":"24","author":"Pantophlet","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.virol.2010.08.028_bb0235","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.virol.2010.08.028_bb0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2796.2007.01820.x","article-title":"Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets","volume":"262","author":"Phogat","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.virol.2010.08.028_bb0245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-065X.1999.tb01282.x","article-title":"The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors","volume":"168","author":"Piguet","year":"1999","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.virol.2010.08.028_bb0250","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2010.08.028_bb0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.virol.2010.08.028_bb0260","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/JVI.75.10.4664-4672.2001","article-title":"DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus","volume":"75","author":"Pohlmann","year":"2001","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.virol.2008.02.007","article-title":"Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination","volume":"375","author":"Polonis","year":"2008","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0270","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/COH.0b013e32832edc50","article-title":"Impact of host cell variation on the neutralization of HIV-1 in vitro","volume":"4","author":"Polonis","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"23","key":"10.1016\/j.virol.2010.08.028_bb0275","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J. Med."},{"issue":"7","key":"10.1016\/j.virol.2010.08.028_bb0280","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.virol.2010.08.028_bb0285","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1128\/jvi.71.6.4847-4851.1997","article-title":"Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization","volume":"71","author":"Rizzuto","year":"1997","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2010.08.028_bb0290","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1128\/JVI.02660-07","article-title":"Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing","volume":"82","author":"Salazar-Gonzalez","year":"2008","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2010.08.028_bb0295","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20090378","article-title":"Genetic identity, biological phenotype, and evolutionary pathways of transmitted\/founder viruses in acute and early HIV-1 infection","volume":"206","author":"Salazar-Gonzalez","year":"2009","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.virol.2010.08.028_bb0300","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1128\/jvi.68.3.1342-1349.1994","article-title":"Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated","volume":"68","author":"Sawyer","year":"1994","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2010.08.028_bb0305","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0310","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/5568","article-title":"Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1\/SIV chimeric virus infections of macaque monkeys","volume":"5","author":"Shibata","year":"1999","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0315","doi-asserted-by":"crossref","first-page":"e1000418","DOI":"10.1371\/journal.ppat.1000418","article-title":"Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus","volume":"5","author":"Simon-Loriere","year":"2009","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.virol.2010.08.028_bb0320","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/jvi.69.1.422-429.1995","article-title":"Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro","volume":"69","author":"Spira","year":"1995","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2010.08.028_bb0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nbt957","article-title":"Correction of multi-gene deficiency in vivo using a single \u201cself-cleaving\u201d 2A peptide-based retroviral vector","volume":"22","author":"Szymczak","year":"2004","journal-title":"Nat. Biotechnol."},{"issue":"15","key":"10.1016\/j.virol.2010.08.028_bb0330","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1128\/JVI.75.15.6776-6785.2001","article-title":"Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates","volume":"75","author":"Tokunaga","year":"2001","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2010.08.028_bb0335","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.virol.2010.08.028_bb0340","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1128\/jvi.70.9.6431-6436.1996","article-title":"Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures","volume":"70","author":"Willey","year":"1996","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2010.08.028_bb0345","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.1997.8812","article-title":"Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization","volume":"238","author":"Zhang","year":"1997","journal-title":"Virology"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210005581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210005581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:07:43Z","timestamp":1758586063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682210005581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0042682210005581"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2010.08.028","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2010.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}